{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T20:07:02Z","timestamp":1783714022476,"version":"3.55.0"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2470,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,10,2]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Highly selective inhibitors of the inducible cyclooxygenase\u20102 enzyme (coxibs) have been associated with less gastrotoxicity than nonselective NSAIDs in clinical studies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To evaluate the influence of risk factors for NSAID\u2010induced gastrotoxicity on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We analysed pooled data from two identical double\u2010blind, randomized, 12\u2010week endoscopy studies which compared the gastroduodenal toxicity of placebo (<jats:italic>n<\/jats:italic>=371), rofecoxib 25\u2003mg (<jats:italic>n<\/jats:italic>=390), rofecoxib 50\u2003mg (<jats:italic>n<\/jats:italic>=379), and ibuprofen 2400\u2003mg daily (<jats:italic>n<\/jats:italic>=376) in patients with osteoarthritis. The potential risk factors evaluated were: age (&lt;\u200365, \u2265\u200365\u2003years), sex, race (white, nonwhite), <jats:italic>Helicobacter pylori<\/jats:italic> status, presence of gastroduodenal erosions at baseline, a history of upper gastrointestinal disease, prior NSAID use within 30\u2003days of study entry, and smoking. We also evaluated these factors for possible association with the development of clinically\u2010evident gastrointestinal perforations, ulcers or bleeds over 12\u2003weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Across all treatment groups, the likelihood of detecting endoscopic ulcers, or of clinical presentation with a bleed, over 12\u2003weeks was increased approximately 4\u20135\u2010fold in patients with previous upper gastrointestinal disease (relative risk [95% confidence interval] of 4.2 [2.5, 7.1] for endoscopic ulcers; 3.8 [1.4, 10.6] for bleeds), or those with gastroduodenal erosions at baseline endoscopy (relative risk of 4.4 [2.6, 7.5] for endoscopic ulcers; 5.0 [1.9, 13.5] for bleeds). <jats:italic>H. pylori<\/jats:italic> infection did not increase the risk of endoscopic ulcers or bleeds (relative risk of 1.1 [0.8, 1.6] for endoscopic ulcers; 0.3 [0.1, 0.9] for bleeds). The risk factor sub\u2010group effects were constant across all treatment groups, and the significantly higher incidence of ulcers with ibuprofen as compared to rofecoxib and placebo was maintained in all risk factor subgroups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Gastroduodenal erosions at baseline and a clinical history of upper gastrointestinal disease, but not <jats:italic>H. pylori<\/jats:italic> colonization, increased the risk for endoscopically\u2010detected ulcers and clinical bleeds. Rofecoxib did not magnify the risk in any of the patient subgroups studied.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01007.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:10Z","timestamp":1047354190000},"page":"1593-1601","source":"Crossref","is-referenced-by-count":48,"title":["Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials"],"prefix":"10.1111","volume":"15","author":[{"given":"C. J.","family":"Hawkey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Laine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. E.","family":"Harper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. U. I.","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For The Rofecoxib Osteoarthritis Endoscopy Multinational Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(17)44821-6"},{"key":"e_1_2_6_3_2","doi-asserted-by":"crossref","first-page":"12866","DOI":"10.1016\/S0021-9258(18)98774-0","article-title":"TIS10, a phorbol ester tumor promoter\u2010inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase\/ cyclooxygenase homologue","volume":"266","author":"Kujubu DA","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.25.12013"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI117060"},{"key":"e_1_2_6_6_2","first-page":"551","article-title":"Rofecoxib [Vioxx, MK\u20100966; 4\u2010(4\u2032\u2010methylsulfonylphenyl)\u20103\u2010phenyl\u20102\u2010(5H)\u2010furanone]: a potent and orally active cyclooxygenase\u20102 inhibitor. Pharmacological and biochemical profiles","volume":"290","author":"Chan CC","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70113-X"},{"key":"e_1_2_6_8_2","first-page":"S196","article-title":"MK\u20100966, a specific COX\u20102 inhibitor, has clinical efficacy comparable to diclofenac in the treatment of knee and hip osteoarthritis (OA) in a 26\u2010week controlled clinical trial","volume":"41","author":"Cannon G","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_9_2","first-page":"S196","article-title":"MK\u20100966, a specific COX\u20102 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6\u2010week controlled trial","volume":"41","author":"Saag K","year":"1998","journal-title":"Arthritis Rheum"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.282.20.1929"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70334-3"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701672"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.1997.v112.pm9024292"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5107(94)70067-2"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0046-8177(94)90191-0"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(98)00071-0"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)04206-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381105"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803123381104"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00550.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.9.937"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91843-0"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-10-787"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-114-4-257"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01007.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01007.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01007.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T10:04:29Z","timestamp":1697537069000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01007.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,2]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2001,10,2]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01007.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01007.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,10,2]]}}}